EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

The Russian drug market slightly fluctuated in 2018

The Russian drug market slightly fluctuated in 2018 The Russian drug market slightly fluctuated in 2018
The Russian drug market slightly fluctuated in 2018 The Russian drug market slightly fluctuated in 2018

What's new?

There was a slight decrease observed in the average expenses of Russians for the purchase of medicines, and the average cost of packaging increased from the last year, as described in Retail Audit Data of FPP in the Russian Federation form January to September 2018.

As per the Retail Audit Data of FPP in the Russian Federation form January-September 2018, the volume of the Russian pharmacy market grew by 6% in Ruble terms and by 1% in dollars and reached to 660.183 billion rubles. In physical terms, the volume of sales of drugs declined relative to the same period of 2017 by 1% and was equal to 3.244 billion rubles. A slight decrease observed in the average expenses of Russians for the purchase of medicines, and the average cost of packaging increased from the last year.

The top ten companies accumulated 34.2% of the Russian market in the first nine months of 2018. The top three international nonproprietary names (INNs) and group names Ibuprofen, combination Diosmin and Hesperidin, and Xylometazoline have not changed. Bisoprolol shifted up to the fourth rank, whereas the earlier less dynamic Pancreatin migrated down to rank five, Rivaroxaban and Ethylmethylhydroxypyridine to eighth and ninth, respectively. The total share of the top ten, raised from 9.6% to 9.8%.

Also, some of the leading ATC groups rating in the country's market remained unchanged. The group M01 anti-inflammatory and antirheumatic products and C09 Preparations influencing the renin-angiotensin system continue to occupy first two positions. B1 Anticoagulants shifted up to rank five from ninth, and G03 Sex hormones shifted from four to three rank. The last line of the rating was grasped for the first time by C05 Angioprotectors. Concurrently, five groups (J01 Antibacterial preparations for systemic use, R01 Nasal preparations, J05 Antivirals for systemic use, N02 Analgesics, and A07 Antidiarrheal, intestinal anti-inflammatory and antimicrobial drugs) dropped by one rating position. On the whole, the share of the top ten ATC groups estimated for 36.3%. These findings are of the first nine months of 2018. 

Source:

Remedium

Article:

DRUGSTORE MARKET OF THE DRUG OF RUSSIA: THE RESULTS OF THE FIRST NINE MONTHS OF 2018.

Comments (2)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: